Increased Anticholinergic Agent Use With Co-prescription of CYP2D6-Inhibiting SSRIs and Risperidone, but not Aripiprazole: A Nationwide Cohort Study
Schizophrenia Bulletin · 20.08.2026 · 52 (5)
DOI: 10.1093/schbul/sbaf189 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Schizophrenia Bulletin, online erschienen am 29.10.2025. Verfasst von Wonsuk Shin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Medicine, CHA University, Seongnam-si 13488, Republic of Korea. Hauptthemen laut MEDLINE: Aripiprazole, Risperidone, Cytochrome P-450 CYP2D6 Inhibitors, Selective Serotonin Reuptake Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Research-Driven Hospital R&D, CHA Bundang Medical Center.
Abstract (Originalsprache)
Background and Hypothesis Co-prescription of selective serotonin reuptake inhibitors (SSRIs) and second-generation antipsychotics is common in the management of schizophrenia. However, the real-world clinical impact of cytochrome P450 (CYP)-mediated drug-drug interactions (DDIs) remains unclear. We investigated whether the co-prescription of risperidone or aripiprazole with SSRIs that differ in their CYP2D6 inhibition potential is associated with an increased burden of extrapyramidal symptoms (EPS). Study Design Using the Korean National Health Insurance Service database (2002-2022), we identified 4100 patients with schizophrenia who were treated with one of four medication combinations: risperidone plus escitalopram (Risp+Esc; n = 1611), risperidone plus fluoxetine/paroxetine (Risp+CYP2D6i; n = 1051), aripiprazole plus escitalopram (Arip+Esc; n = 1025), or aripiprazole plus fluoxetine/paroxetine (Arip+CYP2D6i; n = 413). The primary outcome was the mean proportion of days covered (PDC) by anticholinergic agents, used as a proxy for EPS burden. Groups were compared using multivariate analysis of covariance, adjusting for confounders. Study Results The Risp+CYP2D6i group had a significantly higher mean PDC for anticholinergics compared with the Risp+Esc group (56.4% vs. 47.3%; F = 23.98, P < .0001). Conversely, no significant difference was observed between the Arip+CYP2D6i and Arip+Esc groups (26.1% vs. 28.6%; F = 1.47, P = .225). The use of zolpidem and mood stabilizers was also significantly higher in both CYP2D6i groups. Conclusions Co-prescription of strong CYP2D6-inhibiting SSRIs with risperidone, but not aripiprazole, is associated with a significant increase in anticholinergic use, providing large-scale, real-world evidence of a clinically meaningful DDI. These findings underscore the importance of considering SSRI metabolic profiles to mitigate EPS risk in patients treated with risperidone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, School of Medicine, CHA University, Seongnam-si 13488, Republic of Korea.
- Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam-si 13496, Republic of Korea.
- Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Seoul 06351, Republic of Korea.
- Department of Psychiatry, CHA Ilsan Medical Center School of Medicine, CHA University, Goyang-si 10444, Republic of Korea.
- Department of Pharmacology, School of Medicine, CHA University, Seongnam-si 13488, Republic of Korea.
Förderung
- Research-Driven Hospital R&D
- CHA Bundang Medical Center
Zitieren
APA
Shin, W., Lee, D. H., Hong, M., Kim, M. K., Yoo, H., Lee, Y. S., & Jung, S. (2026). Increased Anticholinergic Agent Use With Co-prescription of CYP2D6-Inhibiting SSRIs and Risperidone, but not Aripiprazole: A Nationwide Cohort Study. Schizophrenia Bulletin, 52(5). https://doi.org/10.1093/schbul/sbaf189
Vancouver
Shin W, Lee DH, Hong M, Kim MK, Yoo H, Lee YS, et al. Increased Anticholinergic Agent Use With Co-prescription of CYP2D6-Inhibiting SSRIs and Risperidone, but not Aripiprazole: A Nationwide Cohort Study. Schizophrenia Bulletin. 2026;52(5). doi:10.1093/schbul/sbaf189
BibTeX
@article{Shin2026,
author = {Shin, Wonsuk and Lee, Dong Hyeon and Hong, Minseok and Kim, Min-Kyoung and Yoo, Hyounggyoon and Lee, Yil-Seob and Jung, Sra},
title = {Increased Anticholinergic Agent Use With Co-prescription of CYP2D6-Inhibiting SSRIs and Risperidone, but not Aripiprazole: A Nationwide Cohort Study},
journal = {Schizophrenia Bulletin},
year = {2026},
volume = {52},
number = {5},
doi = {10.1093/schbul/sbaf189}
}
EUVIMED